SIRPA and cancer: Owing to decorating with Sirpα variants, engineered exosomes could target CD47-overexpressing cancer cells, regulate macrophage phagocytosis through disruption of CD47-Sirpα interaction and lead to innate and adaptive immune responses against cancer.